Blood Culture Identification Panels
GenMark’s ePlex blood culture Identification panels (ePlex BCID) provide broad coverage of organisms that cause sepsis, aiding in more timely critical treatment decisions.
ePlex BCID enables physicians to rapidly identify clinically relevant bloodstream infections and their resistance genes while also ruling out blood culture contamination which can then lead to faster treatment decisions.
EXCEED YOUR EXPECTATIONS
Sepsis is a race against time, get a rapid ID from the most comprehensive panel
59 Distinct reportable targets
Rapid time to result includes resistance markers
Includes a control for rare gram stain misses
The Shortest Hands On Time Possible
The early identification of sepsis is critical to ensuring the best possible patient outcome. GenMark have not only developed a rapid system but also one that requires minimal hands on time for the operator. The simple to use system requires minimal training.
1. Load Sample
2. Load Cartridge
3. Report Results
The difference In Speed Is Clear
2 Minute setup
Since traditional diagnostic methods can take days to identify the causative agents of sepsis, 20-30% of patients receive ineffective initial antibiotic therapy, and it is estimated that for every hour effective antibiotics are delayed, the mortality rate for sepsis increases up to 7.6%. Therefore early identification of the cause of sepsis is critical to ensuring better patient outcomes.
Bacterial and fungal organisms responsible for greater than 95% of blood stream infections and their associated resistance genes can be identified in about 1.5 hours after initial bottle culture, saving critical time to diagnosis.
ePlex BCID saves days compared to conventional methods and is designed to:
- Decrease time to appropriate antimicrobial treatment
- Reduce hospital length of stay and overall costs
- Improve antibiotic stewardship and infection control
- Improve patient outcomes
Comprehensive Coverage of Pathogens and Resistance Genes
Gram Positive Targets
Bacillus cereus group
Bacillus subtilis group
Streptococcus agalactiae (GBS)
Streptococcus anginosus group
Streptococcus pyogenes (GAS)
Gram Negative Targets
Enterobacter (non-cloacae complex)
Enterobacter cloacae complex
GenMark Dx and ePlex are registered trademarks of GenMark Diagnostics Inc.
 IDSA: Better Tests Better Care, The Promise of Next Generation Diagnostics.
 Kumar, et. al., Crit Care Med 2006 Vol. 34, No. 6
 Detection rate is based on panel inclusivity compared to the GenMark prospective clinical trial database and an additional clinical data set (Potula, et. al., (2015) MLO), and is not a sensitivity/performance claim.